FUS

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.C. Dox 1450 P.O. Dox 1450 Alexandria, Vinginia 22313-1450 www.uspto.gov

FILING OR 371 APPL NO. ART UNIT FIL FEE REC'D ATTY.DOCKET NO DRAWINGS TOT CLMS IND CLMS (c) DATE 10/763.794**~** 01/22/2004**~** 1028 PC25687A 17 14 6

28523 PFIZER INC. PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD GROTON, CT 06340

CONFIRMATION NO. 7927

FILING RECEIPT

OC000000012471887

Date Mailed: 04/28/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) CHRISTOPHER

Christoper Ian Dallman, Sandwich, UNITED KINGDOM; Andrew Kevern Hills, Sandwich, UNITED KINGDOM; James Gerard McGovern, Sandwich, UNITED KINGDOM: Richard Anthony Storey, Sandwich, UNITED KINGDOM;

Assignment For Published Patent Application

Pfizer Inc;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/449,185 02/21/2003 and claims benefit of 60/508,051 10/01/2003

Foreign Applications

UNITED KINGDOM 0303097.0 02/11/2003 UNITED KINGDOM 0321309.7 09/11/2003

If Required, Foreign Filing License Granted: 04/28/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

INOTE TO THE ATTORNEY.

Patent Application Attorney Docket No.PC25687A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Commissioner for Patents Box Offe Filing Receipt, P. O. Box 1450, Alexandria, VA 22313-1450 on this 21 day of July 2004	D:
By Steve Granham	_
(Signature of person mailing) Irene Grantham	_
(Typed or printed name of person)	_

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Christopher Ian Dallman, et:

APPLICATION NO.: 10/763,794

FILING DATE: January 22, 2004

TITLE: CRYSTALLINE THERAPEUTIC AGENT

Hon. Commissioner for Patents Mail Stop OITE Filing Receipt P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

REQUEST FOR CORRECTED NON-PROVISIONAL APPLICATION FILING RECEIPT

Please correct the filing receipt for the above-identified provisional patent application as follows:

The first Inventor's name was misspelled on the Application Data Sheet. Please correct the first Inventor's name to read: Christopher Ian Dallman. A new application data sheet reflecting the correct spelling of the Inventor's name is enclosed.

The Missing Parts will be submitted under separate cover.

A copy of the original filing receipt is attached upon which the above changes have been noted.

Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 715-4288

Respectfully submitted,

Attorney for Applicant(s)

Reg. No. 47,811



Title

Crystalline therapeutic agent

Preliminary Class

424

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).